- Home
- KURA vs FSCO Comparison
KURA vs FSCO Comparison
Compare KURA & FSCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- FSCO
- Stock Information
- Founded
- KURA 2014
- FSCO 2013
- Country
- KURA United States
- FSCO United States
- Employees
- KURA N/A
- FSCO N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- FSCO Trusts Except Educational Religious and Charitable
- Sector
- KURA Health Care
- FSCO Finance
- Exchange
- KURA Nasdaq
- FSCO Nasdaq
- Market Cap
- KURA 1.3B
- FSCO 1.3B
- IPO Year
- KURA N/A
- FSCO N/A
- Fundamental
- Price
- KURA $15.92
- FSCO $6.55
- Analyst Decision
- KURA Strong Buy
- FSCO
- Analyst Count
- KURA 7
- FSCO 0
- Target Price
- KURA $29.83
- FSCO N/A
- AVG Volume (30 Days)
- KURA 821.5K
- FSCO 709.7K
- Earning Date
- KURA 11-07-2024
- FSCO 01-01-0001
- Dividend Yield
- KURA N/A
- FSCO 11.44%
- EPS Growth
- KURA N/A
- FSCO N/A
- EPS
- KURA N/A
- FSCO N/A
- Revenue
- KURA N/A
- FSCO N/A
- Revenue This Year
- KURA N/A
- FSCO N/A
- Revenue Next Year
- KURA N/A
- FSCO N/A
- P/E Ratio
- KURA N/A
- FSCO N/A
- Revenue Growth
- KURA N/A
- FSCO N/A
- 52 Week Low
- KURA $9.06
- FSCO $4.08
- 52 Week High
- KURA $24.17
- FSCO $6.00
- Technical
- Relative Strength Index (RSI)
- KURA 34.68
- FSCO 47.69
- Support Level
- KURA $16.55
- FSCO $6.49
- Resistance Level
- KURA $19.73
- FSCO $6.56
- Average True Range (ATR)
- KURA 0.98
- FSCO 0.08
- MACD
- KURA -0.05
- FSCO -0.02
- Stochastic Oscillator
- KURA 8.86
- FSCO 21.15
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
About FSCO FS Credit Opportunities Corp.
FS Credit Opp Corp. is a closed-end management investment company. The Fund's primary investment objective is to generate an attractive total return consisting of a high level of current income and capital appreciation, with a secondary objective of capital preservation. The Fund seeks to achieve its investment objectives by focusing on strategies such as Opportunistic Credit (including event-driven and market price inefficiencies), Special Situations, and Capital Structure Solutions.